Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy

Abstract excerpt

Dear Editor, Tumors evade immune surveillances, in part via negative regulatory pathways (also called checkpoints) that also regulate immune tolerance to autoimmunity (Thommen et al., 2018). Checkpoint inhibitor therapy, i.e., anti-CTLA-4 and anti-PD-1, has been approved to be an effective therapeutic approach in a variety of cancers (Mariathasan et al., 2018). However, only a subset of cancer patients shows...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Immune Cell Function and Interaction
• Share to Immunotherapy and Immune Responses